NAV

GW-3965

Identification

Generic Name
GW-3965
DrugBank Accession Number
DB03791
Background

GW-3965 is a liver X receptor ligand.

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 582.052
Monoisotopic: 581.194456185
Chemical Formula
C33H31ClF3NO3
Synonyms
Not Available
External IDs
  • GW 3965
  • GW 3965A
  • GW-3965
  • GW-3965A
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UOxysterols receptor LXR-betaNot AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Trifluoromethylbenzenes / Benzylamines / Phenol ethers / Phenoxy compounds / Phenylmethylamines / Chlorobenzenes / Alkyl aryl ethers / Aralkylamines / Aryl chlorides / Amino acids
show 10 more
Substituents
Alkyl aryl ether / Alkyl fluoride / Alkyl halide / Amine / Amino acid / Amino acid or derivatives / Aralkylamine / Aromatic homomonocyclic compound / Aryl chloride / Aryl halide
show 25 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
diarylmethane (CHEBI:79995)
Affected organisms
Not Available

Chemical Identifiers

UNII
6JI5YOG7RC
CAS number
405911-09-3
InChI Key
NAXSRXHZFIBFMI-UHFFFAOYSA-N
InChI
InChI=1S/C33H31ClF3NO3/c34-32-27(15-8-17-30(32)33(35,36)37)22-38(18-9-19-41-28-16-7-10-24(20-28)21-31(39)40)23-29(25-11-3-1-4-12-25)26-13-5-2-6-14-26/h1-8,10-17,20,29H,9,18-19,21-23H2,(H,39,40)
IUPAC Name
2-{3-[3-({[2-chloro-3-(trifluoromethyl)phenyl]methyl}(2,2-diphenylethyl)amino)propoxy]phenyl}acetic acid
SMILES
OC(=O)CC1=CC=CC(OCCCN(CC(C2=CC=CC=C2)C2=CC=CC=C2)CC2=CC=CC(=C2Cl)C(F)(F)F)=C1

References

General References
Not Available
KEGG Compound
C15631
PubChem Compound
447905
PubChem Substance
46507779
ChemSpider
394865
BindingDB
19992
ChEBI
79995
ChEMBL
CHEMBL59030
ZINC
ZINC000003966253
PDBe Ligand
965
PDB Entries
1pq6 / 3ipq / 4nqa

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility7.9e-05 mg/mLALOGPS
logP7.41ALOGPS
logP5.52Chemaxon
logS-6.9ALOGPS
pKa (Strongest Acidic)3.88Chemaxon
pKa (Strongest Basic)8.54Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area49.77 Å2Chemaxon
Rotatable Bond Count14Chemaxon
Refractivity156.04 m3·mol-1Chemaxon
Polarizability58.88 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9794
Blood Brain Barrier+0.8116
Caco-2 permeable+0.5922
P-glycoprotein substrateSubstrate0.5404
P-glycoprotein inhibitor IInhibitor0.8176
P-glycoprotein inhibitor IIInhibitor0.6448
Renal organic cation transporterInhibitor0.5283
CYP450 2C9 substrateNon-substrate0.8036
CYP450 2D6 substrateNon-substrate0.6018
CYP450 3A4 substrateSubstrate0.5208
CYP450 1A2 substrateNon-inhibitor0.6191
CYP450 2C9 inhibitorNon-inhibitor0.5664
CYP450 2D6 inhibitorInhibitor0.5942
CYP450 2C19 inhibitorNon-inhibitor0.5223
CYP450 3A4 inhibitorNon-inhibitor0.6415
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7195
Ames testNon AMES toxic0.7429
CarcinogenicityNon-carcinogens0.7976
BiodegradationNot ready biodegradable0.9966
Rat acute toxicity2.7280 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6569
hERG inhibition (predictor II)Inhibitor0.7344
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-001r-0000090000-5afffbac64076b43879e
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-0502090000-dbe8f8b96e42212e77df
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-001i-0603190000-20e60c8024614ac7bb18
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-053r-9602020000-bd7f6a3d032e21526960
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a59-3900010000-7008379dddd6079a2543
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-053u-2900120000-c29a12d98fd5c4d612c3
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-218.82341
predicted
DeepCCS 1.0 (2019)
[M+H]+221.21896
predicted
DeepCCS 1.0 (2019)
[M+Na]+227.13148
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Oxysterols receptor LXR-beta
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Nuclear receptor. Binds preferentially to double-stranded oligonucleotide direct repeats having the consensus half-site sequence 5'-AGGTCA-3' and 4-nt spacing (DR-4). Regulates cholesterol uptake t...
Gene Name
NR1H2
Uniprot ID
P55055
Uniprot Name
Oxysterols receptor LXR-beta
Molecular Weight
50973.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]

Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52